Literature DB >> 11229618

Acute and long-term treatment of catatonia with risperidone.

B Hesslinger1, J Walden, C Normann.   

Abstract

Catatonia is a rare but difficult-to-treat disorder. Here, we report on the case of a schizophrenic patient who developed several episodes of severe catatonia after suffering from adequately treated Lyme disease with encephalitis. The catatonic stupor was not responsive to typical neuroleptics and benzodiazepines. After the medication was changed to risperidone, there was a dramatic and persistent improvement of the patient's condition. Two relapses during the follow-up period over five years were caused by dose reductions. Risperidone might be a promising drug in the treatment of acute catatonia and in preventing further episodes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229618     DOI: 10.1055/s-2001-15190

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  5 in total

Review 1.  Catatonia in patients with autism: prevalence and management.

Authors:  Luigi Mazzone; Valentina Postorino; Giovanni Valeri; Stefano Vicari
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

2.  Subdural haematoma presenting as catatonia in a 20-year-old male: a case report.

Authors:  Bawo Onesirosan James; Joyce Ohiole Omoaregba; Ambrose Onivefu Lawani; Charles Onyenibedi Ikeji; Nosa Godwin Igbinowanhia
Journal:  Cases J       Date:  2009-09-03

3.  Catatonia associated with initiating paliperidone treatment.

Authors:  Nathanael J McKeown; James H Bryan; B Zane Horowitz
Journal:  West J Emerg Med       Date:  2010-05

4.  The catatonic dilemma expanded.

Authors:  Heath R Penland; Natalie Weder; Rajesh R Tampi
Journal:  Ann Gen Psychiatry       Date:  2006-09-07       Impact factor: 3.455

5.  Lorazepam-Resistant Catatonia in an Antipsychotic-Naïve 24-Year-Old with Psychotic Symptoms.

Authors:  Juan Pablo Lucchelli; Stamatia Kourakou; Laia Pérez de Lucia Bové; Daniel Diaz Rodriguez
Journal:  Case Rep Psychiatry       Date:  2020-04-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.